Trial Information

Summary: A Phase II Evaluation of Triapine (NCI-Supplied Agent: NSC #663249, IND #68338)) in Combination with Cisplatin (Commercially Available: NSC #119875) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma [GOG 0126-o]

This research study is for women who have ovarian or primary peritoneal cancer that has failed to respond to initial chemotherapies or has re-grown after surgery, radiation therapy, or other forms of therapy.
The purpose of this study is to determine the safety and effectiveness of the drug Triapine in combination with the chemotherapy drug cisplatin in treating ovarian or primary peritoneal cancer. This study will also help to determine the types and severity of side effects caused by treatment with this combination of drugs.
Study participation may continue as long as there is evidence that your tumor is not growing and the study doctor determines it is safe for you to continue.
No Compensation Provided

Patient Inclusion/Exclusion Criteria:

You may be eligible for this study if you are
-18 years of age or older
-have recurrent or persistent epithelial ovarian or primary peritoneal carcinoma

You will not be eligible for this study if you
-are pregnant or breastfeeding
-have a serious cardiac and/or pulmonary disease
-have a hearing impairment

If you would like to learn more about participating in this study, please send an e-mail message using the form below.